Saw Palmetto for PCOS/PMOS: No Human Trial Found, No Established Dose

Our searches found no human trial testing saw palmetto in a PCOS or PMOS population. Human studies used hair-loss formulas in other populations.

They did not test facial hair, acne, cycles, fertility, or a PCOS dose. The 2026 PCOS study was conducted in rats. That supports a hypothesis for future research, not a treatment recommendation or dose for a woman with PCOS.

Does the evidence match your goal?

• Facial hair or acne: Neither of the two newer human hair trials reviewed below tested either outcome. Our separate outcome search also found no efficacy trial for either one. Scalp-hair studies cannot answer this.
• Lower testosterone or DHT in PCOS/PMOS: No human PCOS trial tested this. A 2026 study used a letrozole-induced rat model, and one non-PCOS hair trial reported a DHT result. Neither establishes hormone lowering in women with PCOS (Taha et al. 2026; Sudeep et al. 2023).
• Cycles, ovulation, or fertility: Our outcome search found no human trial testing these outcomes. Animal findings cannot establish a fertility benefit, cycle effect, human dose, or safety while trying to conceive.
• Scalp thinning: The broader evidence consists of small studies of oral or topical products, often in men or with multiple ingredients. Two newer trials found preliminary hair signals for their exact proprietary formulations. They do not establish a PCOS effect or a result from another bottle (Sudeep et al. 2023; Ablon 2026).
• Dose: No PCOS dose has been established. Doses from rat studies and different proprietary formulas are not interchangeable instructions.

Why “blocks DHT” is not an answer

Saw palmetto extracts are often described as 5-alpha-reductase inhibitors. That enzyme converts testosterone into dihydrotestosterone, or DHT. This gives researchers a reason to test the ingredient. It does not tell us whether taking it changes a symptom that matters to a woman with PCOS.

A plausible mechanism is only the first link in the chain. An extract must inhibit the enzyme in humans at the amount taken, change the relevant hormone in women with PCOS, and then improve the symptom being treated. Current evidence does not establish that chain for facial hair, acne, cycles, or fertility.

The scalp-hair literature contains several other small trials and cohorts of oral or topical saw-palmetto-containing products, often in men and often using multi-ingredient formulas. NCCIH concludes that the evidence is too limited to determine effectiveness. The two newer proprietary trials below add formulation-specific signals, not a class-wide result (NCCIH).

What the human hair studies actually tested

The 2023 trial randomized 80 adults aged 18 to 50 with mild to moderate androgenetic alopecia to an oral capsule, oral placebo, topical formula, or topical placebo. The 400 mg oral capsule contained 100 mg of VISPO, the proprietary saw palmetto oil. Seven participants withdrew, so outcomes were analyzed in 73 completers. The paper's sex counts do not reconcile with those completer totals, and efficacy and DHT results were not reported separately for women. The oral and topical groups had favorable results on some measures of shedding and density, and the oral group had a lower DHT result. The anagen-to-telogen ratio did not change significantly. Vidya Herbs manufactured VISPO and employed four of the six authors, although the paper declared no conflicts (Sudeep et al. 2023).

The 2026 trial enrolled 60 healthy adults with self-perceived thinning hair. Forty received a proprietary 160 mg extract and 20 received placebo for 180 days. Hair-count and density outcomes favored the extract. The female-subgroup reporting is internally inconsistent: the 180-day paper calls the subgroup menopausal but prints full-arm sample sizes in its subgroup tables, while the 90-day report of the same cohort describes 15 treated nonchildbearing women who could be premenopausal or menopausal. Hormone markers were not measured, and the study did not test PCOS, facial hair, acne, cycles, or fertility. The 90-day report says Valensa International, the extract's manufacturer, sponsored the study. ClinicalTrials.gov was first submitted on April 3, 2025, after the trial began on December 16, 2024, so it was not prospectively registered. The 180-day paper declares no conflicts and names no funder (Ablon 2025; Ablon 2026).

These trials make a hair-growth hypothesis more credible than a cell study would. They still leave important uncertainty. They are small, use different proprietary preparations, and do not answer whether saw palmetto helps scalp hair loss caused or accompanied by PCOS. They also do not show that any uncharacterized saw palmetto powder or extract will reproduce the result.

When symptoms need prompt assessment

If facial hair or acne is new, severe, or rapidly worsening, especially with voice deepening, increased muscle mass, or another sign of virilization, seek prompt assessment instead of running a supplement experiment. Current guidance uses the speed of change, virilization, biochemical severity, and assay quality to decide how urgently to investigate (Elhassan et al. 2025).

What is the saw palmetto dose for PCOS or female facial hair?

No evidence-based dose has been established for PCOS, PMOS, female facial hair, or hormonal acne.

The numbers seen online come from different preparations and populations. The 2023 hair trial used a 400 mg capsule containing 100 mg of VISPO, a proprietary oil. The 2026 hair trial used 160 mg of a different proprietary extract that delivered 105 mg of specified fatty acids. The rat PCOS study used 160 or 320 mg per kilogram of body weight. An animal dose is not a human dosing instruction, and the milligram amount on one extract does not make another extract equivalent.

None of the tested amounts, 100 mg of VISPO inside the 400 mg trial capsule, 160 mg of the other human extract, or the rat-only doses of 160 or 320 mg per kilogram, can be presented as “the PCOS dose.” There is also no trial-based schedule for female facial hair, acne, cycles, or fertility. A fixed dose and a fixed improvement timeline would be more precise than the evidence allows.

Is saw palmetto safe for women?

NCCIH says saw palmetto has generally been well tolerated in research, with mostly mild digestive symptoms, dizziness, or headache, but it may be unsafe during pregnancy or breastfeeding (NCCIH).

Those studies do not establish safety for every formula or reproductive context. If you are trying to conceive, using fertility treatment, or taking medicines, show the exact product label to the clinician or pharmacist managing that decision before using it.

What to do next

For facial hair, acne, high androgen results, cycle concerns, or fertility, the evidence reviewed here provides no human PCOS basis for using saw palmetto or choosing a dose. See our outcome-by-outcome guide to reducing androgens in women for the evidence and next steps that match the outcome you want to change.

If scalp thinning is the concern, the human studies make the question worth investigating, but they do not establish that another saw-palmetto formula will work or that PCOS caused the loss. The useful next step is a cause-specific hair-loss assessment, not an improvised supplement protocol.

How we checked the evidence

On September 2, 2026, we searched PubMed and ClinicalTrials.gov for saw palmetto or Serenoa repens with PCOS terms. We separately searched PubMed for the ingredient with hirsutism or acne terms and with menstruation, ovulation, or fertility terms. The PCOS search returned reviews and the 2026 rat study; ClinicalTrials.gov returned no registered PCOS study. The outcome searches returned reviews, a case report, and mechanism records, but no efficacy trial for facial hair, acne, cycles, ovulation, or fertility. We also reviewed the two randomized human hair studies above and the current NCCIH evidence and safety summary.